FdaApplication
NDA 021398
Identifiers
- fda_app_no: NDA021398
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2007-10-30 |
Revenue by product
COMBIGAN
| Period | Revenue |
|---|---|
| Q4 2025 | $54.0M* |
| Q3 2025 | $47.0M* |
| Q2 2025 | $36.0M* |
| Q1 2025 | $60.0M* |
| Q4 2024 | $78.0M* |
| Q3 2024 | $62.0M* |
| Q2 2024 | $49.0M* |
| Q1 2024 | $59.0M* |
| Q4 2023 | $66.0M* |
| Q3 2023 | $70.0M* |
| Q2 2023 | $65.0M* |
| Q1 2023 | $71.0M* |
| Q4 2022 | $74.0M* |
| Q3 2022 | $73.0M* |
| Q2 2022 | $92.0M* |
| Q1 2022 | $107.0M* |
| Q4 2021 | $141.0M* |
| Q3 2021 | $128.0M* |
| Q2 2021 | $142.0M* |
| Q1 2021 | $118.0M* |
| Q4 2020 | $134.0M* |
| Q3 2020 | $123.0M* |
| Q2 2020 | $69.0M* |
| Q1 2020 | $0.0M* |
| Q4 2019 | $0.0M* |
| Q3 2019 | $0.0M* |
| Q2 2019 | $0.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| COMBIGAN | BRIMONIDINE TARTRATE; TIMOLOL MALEATE | 0.2%;EQ 0.5% BASE | SOLUTION/DROPS;OPHTHALMIC |
1 product